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The perturbation of membrane immunoglobulin (mIg)' on B lymphocytes can
have diverse effects on B cell physiology . Immature B cells and certain activated B
cell populations are particularly susceptible to inhibition (tolerance) aftermIg cross-
linking (1-4), while mature, restingB cells are characteristically stimulated toDNA
synthesis (4-6) . Because both stimulatory and inhibitory signal transduction appear
to involve similar early biochemical reactions (1, 6), it is of some interest that the
ligand dose requirements for achieving these distinct functional phenomena have
generally been found to differ by one or more orders ofmagnitude (3, 7-10) . This
suggests that the ligand binding requisites for triggering B cell tolerance may be
significantly different from those for directly triggering B cell clonal expansion .
In this report, we have attempted to rigorously evaluate the binding requisites
for eliciting the activation, or alternatively, inactivation ofB lymphocyteDNA syn-
thesis through mIg . With the use of a large panel of anti-human IgM mAbs, we
examine how the site specificity, the affinity, and the valency of epitopes bound on
mIgM affect the capacity for ligand-induced regulation ofDNA synthesis in the ap-
propriately sensitive human B lymphocytes . The data demonstrate that the IgM
binding requisites for inducing inhibition ofB cellDNA synthesis significantly differ
from those for stimulation. These studies maybe revelant to the control of human
B cell clonal expansion by antiidiotype antibodies and rheumatoid factors.
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Materials and Methods
MurineAnti-HumanIgMmAbs andFragments.
￿
All 10 murine anti-human IgM mAbs used
in these studies have been described previously (11, 12) . With the exception of5D7 (IgG2a),
all are of the IgG1 isotype. Fab' fragments ofmost anti-IgM mAbs were obtained by reduc-
tion of the corresponding F(ab')2 fragments derived from pepsin digestion (13) (exceptions
are mAbs 5D7 and IFll, which formed predominately Fab' upon exposure to pepsin) . Un-
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digested intact antibody was removed by passage of digests over protein A-Sepharose (11).
Nonbound F(ab')2 fragments (or Fab' fragments in the cases of mAbs 5137 and IF11) were
further purified by sieving through a calibrated Sephacryl S-200 column eluted in 0.01 M
Tris-HCI, 0.15M NaCl, pH 7.3 (TBS), and run at <3 ml/cm 2/h . Analysis of protein in the
concentrated ( ;~r1 mg/ml) single sharp peak by5-20% gradient SDS-PAGE under nonreducing
conditions revealed only one major band with an average mol mass of 110 kD (or 52.4 kD
for the 5137 and 11 711 mAbs) . Production of Fab' fragments from F(aU)2 involved reduction
with 10mM cysteine (Sigma Chemical Co ., St . Louis, MO) and alkylation for 1 1/2 h at
room temperature in the dark with 30mM iodoacetamide (Sigma Chemical Go.). Filtration
through a S-200 column yielded a single peak with an average molecular mass of 52.4 kD
by nonreducing SDS-PAGE .
Iodination ofmAb Fab' Fragments.
￿
Proteins were labeled with carrier-free ' 25Iodine (New
England Nuclear, Boston, MA) by the chloramineT method (14) . Labeled protein and reac-
tants were separated on a PD-10 filtration column (Pharmacia Fine Chemicals, Piscataway,
NJ) (previously equilibrated with 10% BSA-PBS-A and washed extensively withPBS-A until
the OD2so = 0) . The percent TCA precipitable counts in the pooled protein peaks of all
labeled preparations was >90% . Specific activity of the iodinated fragments was determined
by protein quantitation with a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Richmond,
CA) using bovine gamma globulin as the standard (range, 2-6 x 106 cpm/wg). Each Fab'
preparation was then made 1% with respect to BSA.
IgM-bindable activity was determined by passing each labeled Fab' fragment (-26 ng =
-80,000 cpm) over a 1-ml column of IgM-Sepharose containing a vast excess ofIgM (6 mg),
or alternatively, a 1-ml column of mock-coupled Sepharose beads . Labeled protein retrieved
from the control Sepharose columns as nonbound ranged from 98 to 100%, while the IgM-
Sepharose-bindable protein ranged from 85 to 94% .
Most of the iodinated mAb Fab' fragments were also compared in their relative binding
affinities forhumanIgM with unlabeled parent Fab. This involved a competition solid-phase
RIA (12) on polyvinylchloride wells using a limiting amount ofhuman IgM as coating an-
tigen (2 gg/ml in PBS-A) . A constant, saturating concentration of ' 211-Fab' was added to the
wells, together with defined amounts of cold Fab', to achieve various ratios oflabeled to unla-
beled Fab' (1 :8, 1 :4, 1 :2, 1 :1, 2:1, 4:1, 8:1) . After a 16-h incubation at 4°C and washing,
the amount of bound radiolabeled ligand was measured . The expected as well as observed
cpm bound were compared and used as an indicator of the relative binding efficiency of the
iodinated vs. unlabeled Fab'. In all cases tested, the observed and predicted values did not
differ by >50%, indicating that the iodination procedure did not appreciably diminish the
native Fab' binding affinity.
Pentameric and Monomeric Human IgM .
￿
Purified IgM myeloma protein Pan (12) was used
as the source ofhuman pentameric IgM . Monomeric units ofPan-IgM were prepared by
reduction with 0.003M 2-mercaptoethylamine (2-MEA) for one-half h and alkylation with
0.006 M iodoacetamide (15) . Monomer IgM was isolated by sieving the material through
a calibrated Sephacryl S-300 gel filtration column eluted with 0.1 M Tris-HCI, 0.15M NaCl,
pH 8.0, and run at <2.5 ml/cm2/h . Analysis of the fractions from two main peaks and one
very minor peakby 5-15% gradientSDS-PAGE, under both reducing and nonreducing con-
ditions, showed the ascending limb ofthe second peak to consist of nearly pure IgMmonomer
(nonreduced, 212 kD), with a very slight amount of H-L (half-molecules of monomer ;
nonreduced, 97.7 kD) . Final yield of purified IgM monomer was -8% of theoretical
maximum .
Cell Sources .
￿
NonmalignanthumanB lymphocytes were obtained from splenectomies fol-
lowing trauma, surgery for a splenic cyst, and for Felty's syndrome (11). B cell-enriched popu-
lations were obtained by twice rosetting out T cells with neuraminidase-treated SRBCs as
described (11) . When evaluated for cell surface markers by FRCS analysis after indirect im-
munofluorescent staining, these populations were found to contain >85% Ig' and Leu-16
(CD-20)+ B cells, <1% 89bl (CD3)' T cells (16), <2 17o P9 (Leu M3)' monocytic cells (16),
and <4% cells positive for the activation-associated molecule bound by mAb 4F2 (17) .
Leukemic B cell specimens were contributed by Drs . Ilona Szer, Stephanie Seremetis, and
Janet Cuttner. The Bia and Lan clonal cell populations were obtained by leukophoresis ofRUDLCH ET AL.
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patients with chronic lymphocytic leukemia (CLL) . Kon and Lub cells were from patients
with hairy cell leukemia(HCL) and have been described elsewhere (16). At the time ofsam-
pling, all donor patients had peripheral white blood cell counts ;o 262,000 cells/mm3 with
little or no contamination with nonleukemic cells, as confirmed by indirect immunofluores-
cence staining with T cell, monocyte, and B cell-specific mAb probes (16) . FACS analysis
ofthese leukemias with Ig heavy and light chain-specific mAbs and a fluorescein-conjugated
goat F(ab)2 anti-mouse Ig probe revealed the following membrane Ig phenotypes : Bia (p,
8, X), Lan (p, 8, x), Kon (p, 8, x), and Lub (p, 8, x). The B lymphoblastoid cell line Daudi
(tt, 8, x ; American Type Culture Collection, Rockville, MD) was also used for some ligand-
binding experiments . With the exception of Daudi, cells from each source were frozen at
the same time in multiple aliquots and stored in the vapor phase of liquid nitrogen .
Cell Culture Conditions and T Cell Factors.
￿
T cell-depleted splenocytes and leukemic B cells
were cultured at 2-2.5 x 105 cells per well in a volume of 0.2 ml as previously described
(11, 16) . DNA synthesis was assessed by uptake of an 18-h pulse of 1 pCi [sH]thymidine (72.5
Ci/mmol; New England Nuclear, Boston, MA). Where raw data are illustrated, mean (X)
cpm f SEM from three identical cultures are reported . Data indicated asA cpm represent
the difference between the cpm in test vs. control cultures . Index of stimulation (SI) values
represent the quotient obtained by dividing the cpm measured in test wells by the cpm ob-
served in control cultures .
Activated T cell supernatants containing growth factors for B cells were obtained from
cultures of PHA-stimulated mixtures of peripheral blood cells of allogeneic individuals as
described previously (11, 16) . In some experiments, a partially purified B cell growth factor
(BCGF) preparation was used (Cellular Products, Inc ., Buffalo, NY) .
Propidium Iodide Analysis.
￿
The DNA content of individual nuclei from cultured Kon leu-
kemic cells was measured with the FACS IV using propidium iodide (PI) as a marker (5) .
Briefly, cells were centrifuged and stained with 50 pg/ml PI (Sigma Chemical Co .) in 0.1°Jo
sodium citrate and 0 .1% NP-40 detergent (Sigma ChemicalCo.). Approximately 10,000 nuclei
from each sample were analyzed . Debris was excluded from analysis by gating based upon
forward light scatter. The amount ofDNA was assessed by the level offluorescence emission
at 608-655 nm after excitation at 488 nm . Segregation of cells in Go (GI) vs . S, G2, and M
was based upon slope extrapolation as described (18) . Go (G,) cells were considered to be
those falling between the gates set by linear extrapolation of the ascending and descending
limbs of each diploid cell peak to baseline. Cells above the upper gate of the diploid peak
were considered to be in S, G2, orM .
Equilibrium-Binding Analysis.
￿
Assays used the phthalate oil method ofseparating cell-bound
from free ligand (19) . Before assay, cells were enriched for viability (generally>95%) by cen-
trifugation through Ficoll/Hypaque at4'C . The number ofcells used varied, depending upon
the mIgM density of the cell population, the specific activity ofthe mAb Fab! fragment, and
its affinity for IgM . Assays with Bia cells used 1.3-3 .6 x 10'/ml ; those with Dau = 1.2-2.5
x 10' ; Lan = 0.6-1.8 x 10'/ml ; Lub = 2.5-11.9 x 10'/ml ; and KE37 = 2.5 x 10'/ml . Be-
fore each experiment, iodinated mAb Fab' fragments were ultracentrifuged at -100,000 g
for 8 min (Beckman Airfuge, Beckman Instruments, Inc ., Fullerton, CA) with the top one-
half used for analysis .
The equilibrium-binding experiments were performed as follows : 2:3 serial dilutions of
iodinated mAb Fab' fragments in assay medium (DMEM + 1% BSA + 15mM sodium
azide with 50mM 2-deoxy-D-glucose to block potential ligand internalization [20]) were added
to cells inmedium precoated 400-p1 Eppendorftubes to a final vol of 200 pl . Triplicates were
run when label was used alone, and duplicates were used for assessing background binding
(see below). The tubes were slowly rotated at 4°C until equilibrium was reached at 2 h, i.e.,
when a twofold increase in reaction time resulted in a<10% increase inbound ligand (21) .
After incubation, 150 pl ofthe cell mixture was gently layered over 150 pl ofprecooled phtha-
late oils (2 :1 vol/vol mixture of dibutyl/dioctyl phthalate [Kodak]) in 7 x 50 mm (400 pl)
polyethylene microfuge tubes (Beckman Instruments, Inc .) and centrifuged in a microfuge
(Beckman Instruments, Inc.) at 12,000 g for <1 min at 22'C . Separation of the cell pellet
from thenonbound ligand in the aqueous layer was achieved by freezing the tubes at - 70'C
and sawing off the tube tip . The cell-bound cpm in the pellet was determined with agamma250
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counter. The data were analyzed by theLIGANDcomputer program (22) to give the equilib-
rium binding constants (K. in 1/mol or M- ') and the number of epitopes bound by mAb
Fab' ligand, in addition to the percent coefficient of variance of these values (22).
Nonspecific binding of label to cells was always determined in two different ways: (a) by
assaying the binding ofligand to cells in tubes containing a 100 :1 pM ratio ofpentamer IgM
to Fab' ligand and (b) by measuring the binding of iodinated Fab' fragments to the Tlym-
phoblastoid cell line, KE37 . Both gave comparable background levels . In addition, inmany
experiments, unlabeled Fab' was substituted for pentameric IgM, yielding similar results .
Immunoekctron Microscopy.
￿
Techniques detailed elsewhere were used (23, 24) . Briefly, freshly
cleaved mica sheets, onto which a thin film ofcarbon was coated, were serially floated onto :
a 1% tryptophan solution; H2O ; mAb F(aU)2 fragments, IgM monomer, or their immune
complexes in 0.15 M ammonium acetate ; 0.3 M ammonium acetate ; and a 2% uranyl for-
mate staining solution. Monomeric IgM and F(aU)2 antibody were diluted in 0.5 M ace-
tate to yield a 1 :1 ratio at 1-3 gg/ml total protein. All reagents were placed as large droplets
onto a Teflon ring slide and kept at 4°C . The polished down side of a copper grid was gently
placed upon the carbon film floating on top of the stain . After insuring that the carbon mem-
brane adhered to the grid, the grid-membrane complex was quickly removed from the sur-
face of the staining well, and excess stain was removed by capillary action . In such a proce-
dure, the carbon membrane folds back upon itself and thus traps a thin film ofstain between
two folds of the protein-coated film on the grid . The grids were examined on aJEOL CEM
CX100 electron microscope and photographed at 100,000 diameters magnification . Nega-
tives were printed at a total magnification of x 260,000 for analysis .
Results
Domain and Epitope Specificity of Murine Anti-Human IgM mAbs.
￿
Table I lists the
murine anti-human IgM mAbs used in this study and shows the p chain domain
specificity as well as the likely number of unique epitopes bound by these mAbs .
Evaluation ofAnti-IgM mAb Affinityfor Human mIgM . Results from equilibrium-
binding experiments, performed at 4°C with four different IgM+ clonal B cell
TABLE I
Human IgM Domain and Epitope Specificity of Murine mAbs
" IgM domain specificity was established by inhibition RIAs using both enzy-
matically derived IgM domain fragments and domain-deletion mutant pro-
teins (12) .
mAbs were defined as binding to the same or distinct epitopes based upon com-
petition RIAs (12) . The designations c (c) andd (d) indicate that these mAbs
cannot be unequivocally distinguished as binding to the same or very proxi-
mate sites as the mAbs binding to c and d epitopes, respectively .
mAb
p chain domain
specificity*
Epitope
designationt
XG9 Cpl a
P19 Cpl b
HB57 Cpl c
P24 Cpl C(c)
Mu18 Cp2 d
Mu53 Cpl d(d)
5D7 Cp4 e
4-3 Cp4 f
1G6 Cp4 g
IF11 Cp4 há w
F
a
RUD~ICFi ET AL .
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populations and analyzed by the method of Scatchard {22, 25}, are shown asKa
and reciprocalKa values in Table Ih Hß57 exhibited the greatest averageK while
mAb IFII the least. K a obtained with the different cell populations were comparable
with one another{average variation of 25.2 t 4.8% [X ~ SEM]} . This was simiiar
to the day-to-day average variation of separate determinations made on the same252
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TABLE III
Evaluation of the Valency of the mAb-definable Efritolbes on Human Membrane IgM
Because of lesser reliability ofcell binding data from low affinity ligands, mAbs P19, P24 and 1F11 have
been excluded from this analysis .
The number of epitopes per cell is equal to the number of Fab' molecules bound per cell at saturation as
derived from the Scatchard plot .
$ The number ofepitopes per mIgM molecule was calculated by normalizing all n x 10-4 values to that
ofXG9 Fab' on the basis that this latter Cpl-specific mAb binds to two epitopes per mIgM molecule . The
formula used was the following : normalized number ofepitopes per mIgM molecule formAb x = [(num-
ber ofbound epitopes per cell observed with x) x 2]/number of bound epitopes per cell observed with mAb
XG9 .
II In instances in which >1 equilibrium binding experiment was performed, the average n t SEM are given .
Numbers in parentheses indicate the percent CV of the n value(s) .
cell population of 21.3 t 5.6%. One mAb, XG9, consistently had a significantly
lower affinity on Lub leukemic cells (1.03 t 0.31 x 10'M-1) than on the remaining
three cell populations (meanKa = 6.95 t 1.59 x 10'M-1) . Ka values forthelower
affinity mAbs (P19, P24, and IF11) were determined with less precision in part be-
cause only Dau and Lan, expressing high-density mIgM, yielded useful data and
in part because fewer data points fulfilled the requirement of being 100-fold above
the background binding with excess IgM (21).
Others have previously noted that increases in temperature can either increase
or decrease the measured equilibrium binding constant (27, 28). The available data
do not allow us to determine whetherthemAb intrinsic affinities measured at 4°C
are identical or different from those that occur at 37°C.
Analysis ofthe Stoichiometry ofmAbFab' Binding to mIgM .
￿
The total number ofIgM
epitopes per cell bound by the Fab' fragments at ligand saturation (n) (22, 29, 30)
is shownin Table III . With theclearexception ofmAb 5137, andthe possible excep-
tion ofmAb Mu18, all of the evaluated mAbs bound to a comparable number of
epitopes within each of the cell populations tested . 5137 consistently bound to an
epitope expressed with a two- to threefold greater frequency . This difference is
significant since replicate determinations with 5137, made on the same cell popula-
tion buton separate days, resulted in an average variation of35 t 7% (X t SEM,
range = 2-63%) . The multiple epitopes bound by mAb 5137 Fab' appeared to be
identical since all derived Scatchard plots were generally linear and conformed to
a one-site model when evaluated by theLIGAND computer program(22) (datanot
shown) .
The right hand portion ofTable III listsnormalized values forthe number of epi-
Number of epitopes per cell :
Normalized number of
epitopes
per mIgM molecules$
Proposed
valency per
mAb Fab` Bia- - Lan - Lub - Bia Lan Lub Mean t SEM mIgM molecule
x 10-4
XG9 2 .3 t 0 .1 (3)11 24.2 (4) 2.4 t 0 .4 (30) 2.0 2 .0 2 .0 2.0 2
HB57 1 .9 t 0.5 (2) 17.3 (2) 2 .7 (1) 1 .7 1 .4 2 .2 1 .8 t 0 .2 2
Mu18 1 .3 (3) 12 .7 (3) 2 .1 (3) 1 .1 1 .1 1 .8 1 .3 t 0 .2 2 (1?)
Mu53 2.6 (4) 20 .7 (3) 3.4(7) 2 .3 1 .7 2 .8 2 .3 t 0 .3 2
5137 3.8 (3) 64.4(3) 8 .8 t 2 .1 (3) 3 .3 5 .3 7 .2 5.3 t 1 .1 6(4?)
4-3 2.0 (7) 16.5 (1) 2.6 (4) 1 .8 1.4 2 .2 1 .8 t 0 .2 2
1G6 1 .8 (5) 16.8 (7) 3 .3 t 0.7 (11) 1 .6 1.4 2 .8 1 .9 t 0.4 2RUDICH ET AL.
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topes bound permIgM molecule, based upon the assumption that theCpl-specific
mAbXG9 binds totwodeterminants per molecule . This wasconsidered a valid sup-
position because the two Cpl domains are spaced widely apart on the Fab arms of
monomericIgM (31) andbecause immunoelectron microscopicdata, to be presented
later, supported the existence of a XG9-binding determinant on each FabP arm .
By this analysis, theCu2-specific r Abs HB57 and Mu53, andthe Cp4-specific mAbs
4-3 and 1G6, apparently bind to divalendy expressed determinants on mIgM, the
epitopes presumably arising from each of the two p chains that make up the intact
IgM molecule . The Cw4-specific mAb 5137 appeared to recognize an epitope with
avalency of4-6 permIgM molecule (i.e., 2-3 per u heavy chain) . The Cp2-specific
mAb Mu18 was consistently calculated to bind to <2 but >1 epitopes per mIgM
molecule. This latter findingmayreflect steric hindranceor induced changes in con-
formation that reduce Mu18 Fab access to the second epitope.
Relationship ofAnti-IgMDomain Specificity to Mitogenic PotentialforHumanB Spleno-
cytes. Fig. 1 indicates that, in the presence of30% T cell supernatant as a source
of ancillary growth factors, neither of the Cg1-specific mAbs, directed to two dis-
tinct epitopes, were able to elicit substantial B cellDNA synthesis at any dose tested
(concentration range : 2-1,000 wg/ml) . An additional seven Cwl-specific mAbs that
have been defined as binding to the same epitope or a contiguous determinant to
that ofmAb XG9 (12) also are nonmitogenic or only weakly mitogenic for human
B cells (11 ; data not shown) . In contrast, all but one ofthe Cut-binding mAbs tested
induced substantialDNA synthesis, although the doses required to induce prolifera-
tion varied considerably. Of the four Cp4-directed mAbs, 5137 was exceptionally
mitogenic at low ligand concentrations; mAb 4-3 required high ligand concentra-
tions for significant B cell stimulation ; andmAbs 1G6 and1711 were only very weakly
mitogenic at the highest doses tested .
The above data indicate that while soluble anti-IgM mAbs of Cpl-domain
specificity are impaired in theircapacity fortriggeringhumanB cellDNAsynthesis,
the binding of mAbs to either Cpl or membrane-proximal Cw4 can result in
significant B cell proliferation . Since not all mAbs toCO andCu4elicited the same
degree of stimulation, binding characteristics otherthanIgM domain specificity must
play a critical role in determining mitogenic potential .
Relationship ofAnti-IgMmAbAffinity to Ibtentialfor TriggeringBCellDNA Synthesis.
￿
Fig.
2 describesthecapacity ofindividual mAbs ofdiffering affinities to stimulate in vitro
B cellDNA synthesis at either low (10-20 ug/ml) or high (100-300 wg/ml) concen-
trations . The mean SI achieved by divalent antibodies is plotted as a function of
their intrinsic Fab affinities. Atlow concentrations, only the twohighest affinity anti-
IgM mAbs, i.e ., HB57 and 5137 (Ka = 5.3 and 1.2 x 108M-1 , respectively) in-
duced significant DNA synthesis (Fig. 2 A). Greater concentrations compensated
for diminished ligand affinity and allowed for induction ofDNA synthesis by anti-
bodies with intrinsic affinities of 0.37-4.66 x 10'M-1 (Fig . 2 B) . mAbs with Ka
of<0.37 x 10'M- I were nonstimulatory, even at high ligand concentrations . With
the notable exceptionofmAbXG9, adirect relationship was observed betweenmAb
binding affinity and stimulatorypotential . Aleast squareslinear regression analysis
(excluding mAb XG9 and the lowest affinity antibody IF11), yielded a regression
line of r = 0.985 .
Monogamous Binding Interactions of mAb XG9 with Monomeric IgM .
￿
Immunoelec-254
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FIGURE 3 .
￿
Immunoelectron photomicrograph of immune complexes formed between mAb
F(ab')2 fragmentsXG9 and 1G6 and humanIgM monomer. (A) Panels I and 2 show the human
monomeric IgM molecule alone; Panels 3 and 4, and 5 and 6 show F(ab')2 fragments of mAbs
XG9 and IG6, respectively . (B and C) Immune complexes formed between monomer IgM and
F(ab')2 fragments ofmAb XG9 ; panel C4 indicates the interpretation ofthese photomicrographs
in schematic form, i .e ., monogamous binding of a single mAb F(ab')2 fragment to monomer IgM .
(D and E) Immune complexes formed between monomer IgM and F(ab')2 fragments ofmAb
IG6 with interpretive schematic illustrations of those immune complexes.
tron microscopy was used to evaluate the possibility that Cpl-specific XG9 mAb
might bind to monomeric IgM in a monogamous fashion (30), i.e ., both binding
sites of a singleXG9Ab molecule engaged with epitopes on a single IgM molecule .
Such a finding could explain the nonmitogenic nature of high-affinity mAb XG9,
since ahigh proportion ofmonogamous binding would reduce the amount ofmIgM
crosslinking .
Fig . 3 (panels BI-4 and C1-3) show that XG9 F(ab')2 can indeed bind monoga-
mously to monomericIgM (72% of the observed complexes). The remaining com-
plexes had either one XG9 F(ab')2 bound to two monomeric IgM molecules in a
bigamous manner, or alternatively, XG9 F(ab')2 molecules bound to IgM monomer
via one arm only (data not shown) . The monogamously bound XG9 F(ab')2RUDICH ET AL .
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Effect of mAb affinity upon ability to inhibit leukemic B cell DNA synthesis. The
concentration of intact mAbrequired for 50% inhibition ofleukemic B cell [3Hlthymidine in-
corporation was calculated from dose-response profiles obtained from at least two separate ex-
perimentson both Konand LubHCLB cells (Fig. 4). The mean values areplotted as afunction
of mAb Fab' affinity in M-1. In the case of Lub cells, mAbXG9 is indicated as having alower
affinity, XG9*, than on Kon cells (see legend Table II). The composite data indicate that the
inhibition ofleukemic Bcell DNAsynthesis by intact antibody isrelatively independent ofaffinity,
until an Fab' affinity threshold of ti7 x 106 M-' .
molecules appeared to have more compacted dimensions than when found in free,
nonbound form. This has been previously noted with anti-K mAb bindingto mouse
IgG molecules (23) andis considered to be dueto geometric constraints that prevent
the immune complex from lying on the same flattened plane.
Panels DI-4 and EI-4 of Fig. 3 show the contrasting types of complexes observed
between monomeric IgM and the F(ab')2 fragment of the CV4-specific mAb 1G6.
The results clearly indicate the bivalent nature of the 1G6 epitope. Of the immune
complexes formed, >75% had two 1G6 F(ab')2 molecules bound perIgM monomer
(panelsD3 and 4 andE2-4), whereas theremainderofobserved immune complexes
had only one F(ab')2 bound per molecule of monomer (panels DI and 2 and EI).
Monogamous binding of 1G6 F(ab')2 to monomeric IgM was not detected.
Inhibition ofLeukemic B Cell DNA Synthesis by mAbs Having Cul-, Cut-, and Cu4-
binding Specicities. The ligand-binding requisites for inhibitory signal transduc-
tion were evaluated with two human HCL B cell populations previously shown sen-
sitive to anti-IgM-mediated negative signaling (16). These are: Kon, which can be
induced to in vitroDNAsynthesisby Tcell factor-containing supernatant, andLub,
which synthesizes DNA spontaneously (Fig. 4). All mAbs, irrespective of their IgM
domain specificity, were found to signal inhibition of Kon and Lub leukemic B cell
DNA synthesis at ng/ml concentrations. This signaling required mIgM crosslinking
and did not involve Fc-receptor binding (16).
Amity RequirementforAnti-IgM-mediated Inhibitory Signaling.
￿
Fig. 5 showsthat the
diversity in theinhibitory potential ofcertain mAbs reflects theiraffinity for mIgM.
mAbs that required significantly greater amounts of ligand to achieve 50% inhibi-
tion ofleukemic B cell DNA synthesis, i.e., P19, P24, and IF11, hadthelowest affini-
ties for mIgM. While adirect relationship was notedbetween affinity ofthese threeRUDICH ET AL .
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TABLE IV
Binding Requisites for Stimulatory and Inhibitory Signal Transduction
through Membrane IgM Differ in a Clonal B Cell Population
' 2 x 105Konhairy cell leukemia B cells were cultured with or without HB57 anti-IgM mAbin the presence
or absence of25% T cell supernatant . Proliferation was assessed on day 5 afteran 18-h incubation with
[3H]thymidine . The mean t SEM from triplicate cultures are shown .
t Percent cells in S, G2, orM was determined from day 4 cultures by propidium iodide staining using the
FACS as detailed in Materials and Methods.
ligands and inhibitory potential, concentration-dependent differences in inhibition
by mAbs with Fab' binding affinities >7 .0 x 106 M-1 were not evident . This sug-
gests an affinity threshold for inhibitory signaling by anti-Ig ligands, above which
increases in affinity have aminimal effect . Also notable in Figs . 4 and 5 is that mAb
XG9 was not notably compromised in causing inhibition despite its established propen-
sity for monogamous binding (Fig . 3) .
Binding Requisitesfor Stimulatory and Inhibitory Signal Transduction Differ in a Clonal
BCell Population. The above cumulative data suggest that the ligand binding requi-
sites for triggering inhibition ofDNA synthesis through mIgM are significantly less
demanding than those for stimulatingDNA synthesis . Because stimulation was evalu-
ated with normal B lymphocytes and inhibition was evaluated with leukemic B cell
clones, normal vs. malignant cell phenotype may have accounted for the distinc-
tions . That this is not the case is shown in experiments with an unusualHCL clone,
Kon, which can receive stimulatory, or alternatively, inhibitory signals from anti-
IgM ligands, depending upon its state of activation (16) . In the absence ofT cell
factors, Kon cells respond with very significant levels ofDNA synthesis only to high
concentrations of the highest affinity mAb, HB57 (Table IV) (16 ; data not shown) .
In striking contrast, theT cell factor-induced DNA synthesis ofthe clone is inhibited
by low as well as high doses of all the anti-IgM ligands (Table IV; Fig . 4) . These
data with a clonal B cell population clearly indicate that the differences in ligand
requisites for activating and inhibiting B cell DNA synthesis are not simply reflec-
tive of the malignant vs . normal nature of the cell populations used, but, rather,
represent distinct mIg binding requirements for inducing the two functional outcomes .
Discussion
One principal conclusion of these studies is that the induction of human B cell
DNA synthesis, a requisite for B cell clonal expansion, is primarily determined by
the affinity of the mIgM crosslinking ligands . With one explainable exception, a
direct relationship was notedbetween the intrinsic affinity of a mAb for mIgM and
its mitogenic potential . At high ligand concentrations (100-300 ug/ml), the min-
imal affinity threshold for inducing significant B cellDNA synthesis in the presence
Anti-IgM mAb Ab concentration
uglml
[3H]Thymidine
No T
supernatant
cpm t
uptake (d5)'
+ T
supernatant
SEM
Cells in S, G2,
No T
supernatant
%
or M (d4)t
+ T
supernatant
None - 460 t 40 19,929 t 217 1 .0 8 .1
HB57 2 493 t 13 813 t 146 2 .0 1.4
200 40,596 t 5,980 6,827 t 410 10 .7 4.2260
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of ancillary T cell factors wasKa = -2 x 10'M-1 . At lower ligand concentrations
(10-20 ug/ml) this thresholdwas significantly greater, i.e .,Ka = -1 x 108M-1 . This
is as predicted given the law ofmass action effect of concentration of reactants on
complex formation (21) . Because stimulatory signal transduction by anti-Ig anti-
bodies requires bivalent bindingofthe ligand (6), and becausebivalentmAbbinding
to cell membrane antigens is characterized by at least a 10-100-fold enhancement
in avidity over that exhibited by univalent Fab` fragments (28, 29), it is anticipated
that the minimal bindingavidity ofa soluble anti-IgM ligand required for inducing
human B cell DNA synthesis at high concentrations is in the range of 2 x 108-9
M-1 , and at low concentrations is in the range of 1 x 109'1°M-1 . Our findings that
affinity is a major contributing factor to ligand stimulatory capacity supports and
extends in a quantitativeway the findings ofGoroffet al . (32) with anti-mouse IgD
mAbs .
The only ligand that deviated from adirect linear relationship between intrinsic
affinity and proliferation-inducing capability was mAb XG9. This relatively high-
affinity antibody (Ka = 6.95 x 107M-1) was consistently nonmitogenic for normal
humanB cells, even at concentrations up to 1 mg/ml . Immunoelectron microscopy
provided an explanation by revealing that mAbXG9 has a predilection formonoga-
mous binding to the bivalently expressed CAI epitopes on monomeric IgM. This
tendency is probably due to the comparable spacingbetween CAI epitopes and the
bivalent combining sites of themAb. It is highly likely that monogamous binding
diminishes the stimulatory signaling potentialofthis high-affinity antibody by reducing
its crosslinking potential .
The functional data shown here, as well as cappingstudies(our unpublished results),
suggest that Cg2- and Cg4-specific antibodies have a lower probability ofengaging
in monogamous binding interactions with mIgM than Cg1-specific antibodies .
Monogamous binding may be precluded by the close interactions between homolo-
gous pairs of the Cg2 andCg4 domains (31) as well as by the predicted topographi-
cally polar orientation ofepitopes on each side of the globular paired domain struc-
tures . The findings of Goroff et al . (32) that high-affinity mAbs directed to the Fd
portionofmurineIgDwere ineffective at cappingandstimulatingmouseB cellDNA
synthesis, whereas high affinity mAbs to the Fc portion ofmurine IgD were good
at inducing capping and very mitogenic, are also explainable in this context .
These findings have strong functional implications for antiidiotype antibodies,
since monogamous binding appears to be characteristic ofa substantial proportion
ofandidiotypemAb interactions with both soluble andcell-bound Ig molecules (24,
28, 33) . Those antiidiotype antibodies of the IgG class that bind monogamously
to m1g should be significantly impaired in capacity for directly inducing B cell clonal
expansion, regardless of their affinity for their respective epitopes .
Among the hypotheses initially considered for the diversity in mAb stimulatory
signalingpotentialwas thevalencyofmIgM epitopes recognized by each mAb . Differ-
ences in the epitope univalency (34) or divalency were expected to have significant
effects on the extent to whichmIgM molecules could be crosslinked, i.e ., dimerfor-
mation vs . linear concatemer formation (30) . The studies shown hereonFabbinding
stoichiometry to m1gM exclude this hypothesis, since with one exception, all ofthe
anti-IgM mAbs appeared likely to bind bivalently expressed epitopes .RUDICH ET AL.
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The Cg4-specific mAb, 5137, was unique in its recognition of an epitope with an
apparent valencyof4-6permIgM molecule . Becausethehybridomacloningcondi-
tions, the unusual isotype of this mAb, and the unusual enzymatic fragmentation
characteristics of 5137 all attest to itsmonoclonality, wedo notconsider that theanti-
body preparation represents a mixture of antibodies to distinct determinants . Fur-
ther characterization of the 5137 epitope is in progress.
Of great significance in these studies was the fact that the conclusions regarding
mIgM ligand-binding requisites for stimulation of B cell DNA synthesis did not
applyto inhibition . First, consistent with otherstudies (3, 7-10), theligand concen-
trations for maximal inhibition ofB cell DNA synthesis were orders ofmagnitude
lowerthan those for stimulation . Second, while inhibitory signalingwas clearly affinity
independent at univalent ligand affinities >7.0 x 106M-1 , an upperaffinity thresh-
old formaximal stimulation ofB cellDNA synthesiswasnot detected . Third, while
a high-affinity Cg1-specific mAb with a propensity for monogamous binding to
mIgM was unable to initiate B cell DNA synthesis, the same antibody was quite
competent at causing inhibition. Thesedistinctions indicate that the ligand binding
requisites formIgM-mediated inhibition ofBcellDNAsynthesis are much less rig-
orous than those forB cell clonal expansion and explain the past observations of
Leptin (35) with anti-mouse IgMmAbs . Although inhibitory signaling was here
studied with leukemic B cells, these observations have physiologic significance for
normal B cells since the mechanism for mIgM-mediated inhibition in malignant
B cells is thought to mimic that responsible for at least one form ofB cell tolerance
(1, 2, 36).
Two majorexplanations appear plausible forthe differences in binding requisites .
First, stimulationofDNAsynthesis mayrequire a greater initial crosslinked receptor
cluster, immunon (37), than inhibition . Thus, activation of susceptible cells may
be achieved only with high-affinity ligands which, because of their likely lower dis-
sociation rate (27) and prolonged occupancy, are more capable of stabilizing such
clusters (see Fig. 6 A) . Alternatively, the greater binding requisites for stimulation
may reflect the duration of the stimulatory signalingprocess(Fig. 6 B) . Our unpub-
lished observations, as well as the work of others, have indicated that for S phase
entry of anti-Ig-treated resting B cells, ligand must be present for an interval of
24-36 h (8, 38, 39), while inhibition of DNA synthesis may be achieved after
significantlyshorterligand exposure (36) . This difference becomes particularly rele-
vant when one considers that, after an initial cycle ofcapping and endocytosis, B
cells slowly replace mIgmoleculesand displayvery low-densitymIgM forsome time
(38). Undertheseconditions, continuedB cell signaling by mIgM crosslinking may
be achieved onlyby high-affinity ligands that can remain univalentlyboundto mIgM
for a period of time sufficient for distally located mIgM molecules to diffuse into
proximity . This hypothesis places greaterdemandson the ligands only at laterphases
in B cell activation .
Several recent observations from other laboratories lend support to this second
explanation (Fig . 6 B) . First, anti-Ig ligands that areineffective at inducing theDNA
synthesis of resting B cells have been documented to initiate a number of early
activation-related biochemical changes in B cells that precede, or are concurrent
with, an initial cycle ofmIg capping (18, 40) . Secondly, T cell factor-independent262
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FIGURE 6.
￿
Alternative models formIgM crosslinking events that lead to stimulatory or inhibi-
tory signals forB cell DNA synthesis. (A) Stimulatory andinhibitory signal transduction may
differ in the minimal requisite unit of crosslinked receptors. (B) Unit signal for activation and
suppression of Bcell DNAsynthesismaybe achieved by crosslinking similarnumbersofreceptors.
However, the activation of DNA synthesis may require repeated cycles of mIgM crosslinking
under conditions of extremely low receptor density.
signaling of B cell DNA synthesis by high concentrations of polyclonal anti-IgM
antibodies requires high ligand concentrations at late, but not early intervals in the
stimulation of murine B cells (8, 39).
Although it remainsto be determined whetherthe bindingrequisites forinducing
B cell tolerance are subtly different from those forinducing early activation related
changes in resting mature B cells, the current data are compatible with thehypoth-
esis that requirements forinducing anyearly biochemicalphenomena in Bcells with
acomparable densityof mIgM are the same. Theinhibitory or stimulatoryoutcome
of these early signals will depend upon the activation or differentiation state of the
particular B cell population beingstudied(2, 3, 16). Forearly pre proliferative changes
in stimulated resting B cells to lead to clonal expansion, one of two events is neces-
sary. There is (a) further signalingthrough mIgM crosslinking by ligands that can
form stable complexesof mIgM underconditions oflow m1gM density, and/or there
is (b) signalingby activated class II MHC-restricted helper T cells or theirproducts
(6, 41).
Ourconclusion that tolerogenic signal transduction in susceptible B cellshas much
lower affinity requisites than signal transduction for B cell clonal expansion, would
appear to contradict the conclusions of Riley and Klinman (42) in a murine ex-
perimental system. Onemajor explanationmaybe that the former investigators evalu-
ated B cell stimulation by antigens dependent upon cognate T cell help. The ligand
binding requisites for sufficient B cell endocytosis, processing and presentation ofepitopes to T cells, and stimulation of early Go- Go- changes such as in-
creased m1a levels, which enhance B cell-T cell collaborative interactions, are likely
much less demanding than the bindingrequisites for direct ligand-induced cell cycle
entry (18, 43).
physiological implications of our studies would appear to have the most im-
mediate relevance to the direct, cognate T cell-independent signaling role played by
autologous rheumatoid factors or antiidiotype antibodies in the regulation of B cell
immune responses. Although IgG antiidiotype antibodies with a propensity for
monogamous binding (24, 28, 33) may be compromised in their capacity to directly
signal the clonal expansion of B lymphocytes, they may be active in negatively
regulating the maturation or differentiation of idiotype-positive B cell clones. Fur-
thermore, sincemost human rheumatoid factors appear to be ofrelatively low affinity
(44), it is expected that theseligands may manifest a more direct role in the feedback
of B cell responses than in B cell clonal expansion.
Summary
The ligand binding requisites for membrane IgM-mediated signaling ofhuman
B lymphocyte clonal expansion and B cell tolerance were investigated with a well-
characterized set of soluble murine anti-human IgM mAbs. Evaluation of the im-
pact oftt chain domain specificity, affinity, and binding stoichiometry for membrane
IgM on antibody-induced regulation ofnormal and leukemic B cell DNA synthesis
revealed that the ligand binding requisites for inducing or, alternatively, suppressing
B cell DNA synthesis are significantly different. First, while the induction ofS phase
entry required pglml concentrations of ligand, orders of magnitude lower concen-
trations ofligand sufficed for inhibitory signaling. Second, while an upper affinity
threshold for achieving maximal stimulation of B cell DNA synthesis was never de-
tected, inhibitory signaling by bivalent ligands appeared to become relatively affinity
independent at Fab binding affinities >7.U x 1íï& M- '. Third, while a C1í2-specific
mAb with an enhanced incidence ofmonogamous binding to m1gM was ineffective
at inducing B cell DNA synthesis, the antibody was not significantly compromised
in ability to initiate inhibitorysignals. These differences could be observed in a clonal
B cell population which positively or negatively responded to m1gM ligation de-:
pending upon its state of activation. The accumulated observations indicate that
the ligand binding requisites for inhibitorysignal transduction in human B lympho-
cytes are much less rigorous than those for stimulatory signal transduction and sug-
ogically relevant anti-Ig antibodies are more likely to function
egative feedback regulation of B cell responses than in the direct triggering
of human B cell clonal expansion.
RUDICH ET AL.
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